MEG3 and metabolic dysfunction-associated steatotic liver disease: One of the first studies of lncRNAs in NAFLD fibrosis identified that the expression of MEG3 was decreased in the livers of CCl4-treated mice, when compared to those of oil-fed control animals, and that the expression of MEG3 reduced concordantly with the progression of fibrosis [66].